---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-020064"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T14:34:31.479762+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "low"
source: SEC EDGAR
---

# INmune Bio files investor presentation on INKmune phase I/II in prostate cancer - no specific data disclosed

## Summary
- Preliminary phase I/II results for INKmune in metastatic castration-resistant prostate cancer highlighted in new investor deck.
- No specific efficacy or safety data provided in the 8-K excerpt; full slide content not available.
- Presentation focuses on in vivo activation of memory-like NK cells (mlNK) using INKmune.

## SEC filing metadata
- accession: 0001213900-25-020064
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025020064/0001213900-25-020064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025020064/ea0233142-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-020064
- JSON: https://secwatch.observer/filing/0001213900-25-020064.json
- Plain text: https://secwatch.observer/filing/0001213900-25-020064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.